Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005813 · ClinicalTrials.gov registry record · Phase 1

Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme

A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00005813 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Dartmouth-Hitchcock Medical Center. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005813, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Bispecific antibodies plus white blood cells may be able to locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of combining bispecific antibodies with white blood cells in treating patients who have recurrent or refractory glioblastoma multiforme.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • PROCEDURE conventional surgery
  • BIOLOGICAL bispecific antibody MDX447
  • BIOLOGICAL lymphokine-activated killer cells

Study Locations (1)

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Start Date 1997-03
Est. Completion 2003-01
Phase Phase 1

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005813

The ClinicalTrials.gov registry entry for NCT00005813 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which conventional surgery is the first listed.

NCT00005813 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.

Frequently Asked Questions

What is clinical trial NCT00005813 about?

NCT00005813 is a clinical study titled "Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme". RATIONALE: Bispecific antibodies plus white blood cells may be able to locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of combining bispecific antibodies with white blood cells in tre...

What is the current status of trial NCT00005813?

This trial is currently completed. It is a Phase 1 study. The study started on 1997-03. Estimated completion is 2003-01.

What conditions does trial NCT00005813 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00005813?

The interventions under investigation include: conventional surgery (PROCEDURE), bispecific antibody MDX447 (BIOLOGICAL), lymphokine-activated killer cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT00005813?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005813 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain and Central Nervous System Tumors

All registered trials for this condition

New Hampshire

All trials with a study site in New Hampshire

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.